Investment Thesis
Neurogene is a pre-revenue biotech company with adequate financial resources but zero revenue and significant operating losses of $33.3M. While the strong balance sheet ($237.8M equity, $124.2M cash) provides 4+ years of runway, the lack of commercial traction and persistent operating losses indicate the company remains entirely dependent on unreported clinical and regulatory outcomes.
Strengths
- Strong balance sheet with $237.8M stockholders' equity and no long-term debt
- Excellent liquidity position with $124.2M cash and 13.08x current ratio
- Low liability burden ($25.4M) providing financial flexibility for operations
Risks
- Zero revenue indicates completely pre-revenue stage with no commercial validation
- Large operating losses ($33.3M) and negative operating cash flow ($26.1M) indicate ongoing cash burn
- Binary outcome risk - profitability and success entirely dependent on unreported clinical/regulatory milestones
- EPS deeply negative at -$1.39 with no clear path to profitability
Key Metrics to Watch
- Revenue recognition and first commercial sales timeline
- Operating cash flow trends and cash runway extension
- Clinical trial progress and regulatory approval milestones
Financial Metrics
Revenue
0.0
Net Income
-30.9M
EPS (Diluted)
$-1.39
Free Cash Flow
-26.4M
Total Assets
263.1M
Cash
124.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-13.0%
ROA
-11.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
13.08x
Quick Ratio
13.08x
Debt/Equity
0.00x
Debt/Assets
9.6%
Interest Coverage
-11,116.33x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:32:41.401455 |
Data as of: 2026-03-31 |
Powered by Claude AI